1Department of Medicine, Baylor College of Medicine, Houston, Texas; and 2Department of Physiology, University of Kentucky, Lexington, Kentucky
Submitted 15 February 2005 ; accepted in final form 25 June 2005
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
tumor necrosis factor- receptor double-knockout mice; myogenesis; p38 mitogen-activated protein kinase; dystrophic calcification; contractility
Muscle regeneration takes place in an environment with unusually high TNF- levels. Coincident with the onset of muscle regeneration, the TNF-
level in injured muscle rises dramatically because of a strong increase in TNF-
synthesis by injured myofibers as well as TNF-
released by infiltrating inflammatory cells (7, 10, 43, 46, 50), and myofiber synthesis of TNF-
is positively correlated to regenerating activity (21). At the same time, there is an increase in TNF-
receptor expression in injured muscle fibers (10, 50), suggesting an intrinsic need in injured muscle for increased TNF-
signaling. Recent evidence supports a physiological role for TNF-
in myogenesis. A rapid increase of TNF-
synthesis by C2C12 myoblasts during the early hours of myogenic differentiation is critical for muscle-specific gene expression, suggesting that TNF-
regulates myogenesis as an autocrine or paracrine function (28). TNF-
receptor double-knockout impairs strength recovery of mouse muscle injured by freezing, which suggests the participation of TNF-
in the regulation of muscle regeneration (46). However, the mechanism through which TNF-
participates in the regulation of muscle regeneration is not understood. In the present study, we demonstrate that 1) TNF-
signaling is critical for p38MAPK activation and p38-dependent signaling events required for myogenic differentiation and 2) deficiency in TNF-
signaling impairs muscle regeneration.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Western blot analysis. Western blot analysis was performed as previously described (27) . Antibodies for pan- and phosphorylated p38, ERK1/2, and JNK MAPK were obtained from Cell Signaling Technology (Beverly, MA). Antibodies for pan-myocyte enhancer factor (MEF)-2C (sc-13266), phosphorylated MEF-2C (sc-13920), and p21 (sc-397) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody for myogenin was obtained from the Development Studies Hybridoma Bank at the University of Iowa (Iowa City, IA). Muscle protein extracts were used in all experiments, except for MEF-2C and phospho-MEF-2C, which were analyzed using muscle nuclear extracts prepared according to a protocol described previously (13). Detected protein bands were quantified using optical density (OD) measured with ImageQuant software (Molecular Dynamics). All Western blot analyses were performed two or three times to ensure that the results were repeatable, and representative blots are shown in Figs. 1, 2, and 3. Protein concentration in the extracts was determined using the Bio-Rad protein assay.
Real-time PCR. Total RNA was extracted from excised soleus using RNAzol reagent (TEL TEST, Friendswood, TX). Reverse transcription was performed using a kit from Applied Biosystems (Foster City, CA). Real-time PCR was performed using TaqMan Gene Expression primers and probes for mouse cyclin D1 (assay identification no. Mm00432357_m1; Applied Biosystems) using a 5700 sequence detection system (Applied Biosystems) according to the manufacturer's protocol. The quantity of PCR product was normalized to 18S rRNA determined using TaqMan Gene Expression primers and probes for 18S (no. 4310893E; Applied Biosystems). The standard curve method was used to quantify the PCR products.
Electrophoretic mobility shift assay.
Nuclear extracts were prepared from soleus muscle, and EMSA was performed for NF-B as described previously (13).
Histological studies. Solei collected from mice were fixed in 4% formaldehyde, and paraffin-embedded sections were made and processed for hematoxylin and eosin (H&E) or Von Kassa staining performed by the Baylor Histology Service. Soleus myofiber cross-sectional area (XSA) was measured using ImageJ software (National Institutes of Health, Bethesda, MD). Mean XSA on day 12 were normalized to preinjury (day 0) XSA of soleus from the same type of mice. For immunohistochemical staining with anti-Mac-1, frozen sections of excised soleus (5 µM) were prepared and fixed in acetone for 10 min at 20°C. Sections were treated with 3% H2O2 for 10 min and blocked in 5% BSA for 1 h at room temperature. Incubation with anti-Mac-1 (M1/70.15.11.5.2; Developmental Studies Hybridoma Bank) was performed at 1:50 dilution in blocking buffer for 1 h at 37°C. After sections were washed in PBS, incubation with biotinylated anti-rat secondary antibody was conducted at room temperature for 30 min. Avidin-biotin complex and diaminobenzidine reagent kits (Vector Laboratories, Burlingame, CA) were used according to the manufacturer's protocol to detect the secondary antibody. Counterstaining with hematoxylin was performed for 30 s. Images of stained muscle sections were acquired using MetaVue computer software and a Zeiss Axioplan 2 microscope coupled to a Photometric Cool Snap charge-coupled device camera and then edited using Adobe PhotoShop software. The average number of Mac-1-positive cells observed under a microscope in 0.25-mm2 areas of soleus sections was obtained by counting multiple areas in each section. Means of the average derived from multiple mice were expressed as the inflammation index.
Force-frequency study. Immediately after excision of solei from mice, they were immersed in room temperature Krebs-Ringer solution containing (in mM) 137 NaCl, 5 KCl, 1 NaH2PO4, 24 NaHCO3, 2 CaCl2, and 1 MgSO4. The solution was aerated in a 95% O2-5% CO2 atmosphere. One soleus tendon was tied with 5-0 silk suture to a glass rod; the other tendon was tied to a force transducer (model BG 100; Kulite Instruments, Leonia, NJ) mounted on a micrometer. Soleus muscles sections were subjected to field stimulation using platinum electrodes. Muscle length was adjusted using the micrometer to produce optimum twitch force. The solution was then heated to 37°C, and the temperature was controlled using a digital water bath at 37°C throughout the remainder of the experiment. After a 30-min thermoequilibration period, we determined the force-frequency relationship. Tetanic contractions were stimulated at 1-min intervals (500-ms train duration); between each intermediate frequency (15, 30, 50, 80, 120, 160, and 250 Hz), a maximum tetanic contraction (Po, 300 Hz) was elicited to serve as a reference for changes in force over time. Soleus muscle length that yielded optimum force was measured, and the muscle then was trimmed of tendons and weighed. Force measurements were later normalized for functional cross sections according to the method described by Close (6).
Statistics. Commercial software (SigmaStat; SPSS Science, Chicago, IL) was used to analyze data. Student's t-test or ANOVA was used for analysis as indicated. Differences between groups were considered significant at the P < 0.05 level. Values are reported as means ± SE.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Activation of p38MAPK during muscle regeneration is blocked in p55/p75/ soleus.
We previously showed that TNF- promotes myogenic differentiation in an autocrine fashion in C2C12 myoblasts (28). Among TNF-
receptor-activated signaling events, p38MAPK (26) stands out as a necessary and sufficient mediator of myogenic differentiation (2, 9, 35, 36, 47, 51). The activity of p38 increases dramatically during myogenic differentiation in myoblasts (9, 47) and in injured human muscle (1) or injured myoblasts (49). However, the signal that is responsible for p38 activation during myogenesis in vivo has not been identified, while it is known that p38 activation is independent of the potent myogenic stimulus insulin-like growth factor I (47). To investigate the underlying mechanism for the potential regulatory role of TNF-
in muscle regeneration, we examined activation of p38MAPK in CTX-injured mouse soleus muscle during the course of regeneration as well as its relationship to TNF-
signaling. Using an antibody specific for phosphorylated p38, we found that Western blot analysis revealed that p38 was activated within 1 day after injury and lasted for at least 10 days in WT soleus (Fig.1). Comparing p38 activation in WT and p55/p75/ soleus on day 3 postinjury, when myogenic differentiation was being initiated, we found that activation of p38 was blunted in p55/p75/ soleus, while total p38 levels were not different from those observed in WT soleus (Fig. 2), suggesting a dependence of p38 activation on TNF-
receptor activation during muscle regeneration. On the other hand, we observed no reduction in the activation of ERK1/2 (Fig. 2), a TNF-
-responsive MAPK that stimulates satellite cell proliferation but not differentiation (8). The activity of another TNF-
-responsive MAPK JNK whose role in myogenesis is not well defined, with both inhibitory and stimulatory effects having been reported (20, 32, 39), was not reduced in p55/p75/ soleus either (data not shown). Because TNF-
activates transcription factor NF-
B, which also influences myogenic differentiation (19, 24, 28), we examined whether NF-
B is activated in CTX-injured muscle in a TNF-
signaling-dependent manner. Using EMSA, we observed a similar increase of NF-
B binding activity in WT and p55/p75/ soleus muscle on day 3 postinjury compared with uninjured control (data not shown). Thus NF-
B is activated in injured muscle in a non-TNF-
-dependent manner. These data suggest that TNF-
receptor activation is a critical upstream signal for p38 activation during muscle regeneration.
|
|
|
|
|
|
|
Restoration of contractile force is compromised in regenerating p55/p75/ soleus. Next, we used a physiological approach to evaluate muscle regeneration by determining the restoration of contractile force generated by excised soleus by evaluating the force-frequency relationship. Uninjured soleus excised from WT and p55/p75/ mice (day 0) produced comparable maximal force (Fig. 8), although the force-frequency curve was shifted slightly to the right in p55/p75/ relative to WT. On day 5 postinjury, both types of soleus muscle lost at least 90% of maximal force. On day 12, the maximal force generated by WT soleus recovered to 75.8% of the preinjury level. However, force generated by p55/p75/ soleus was only 53.9% of preinjury level (P < 0.05 compared with day 12 WT). This result corroborates the histological data and confirms that muscle regeneration is impaired in CTX-injured p55/p75/ soleus muscle.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Given the negative image of TNF- in skeletal muscle metabolism because of its involvement in muscle protein breakdown, inflammatory myopathies, and insulin resistance (29, 37), it appears counterintuitive that expression of TNF-
and its receptors by myofibers would increase dramatically during injury-induced regeneration (7, 10, 43, 46, 50), which, along with TNF-
released by infiltrating inflammatory cells, brings about an unusually high level of TNF-
receptor-mediated signaling. Several of the TNF-
-activated signaling molecules are involved in the regulation of myogenesis, including members of the MAPK family and NF-
B. Members of the MAPK family have different roles in myogenesis. p38MAPK is recognized as a necessary and sufficient "switch" that turns on the differentiation program (2, 36, 51), while ERK1/2 stimulates the proliferation of myocytes (8). On the other hand, the role of JNK in myogenesis is not well defined. Both inhibitory and stimulatory effects on myogenesis have been reported for JNK (20, 32, 39). NF-
B also influences myogenic differentiation (19, 24, 28). The dependence of p38 activation on TNF-
is remarkable, considering that the activation of ERK1/2, JNK, and NF-
B was not TNF-
dependent during muscle regeneration. These factors can be activated by multiple cytokines and growth factors in the absence of TNF-
signaling. Although p38 activation has been established as a key event in myogenic differentiation, the upstream signal for p38 activation during muscle regeneration was not identified. We have demonstrated herein for the first time that TNF-
receptors are required for p38 activation during muscle regeneration. Our observations suggest that the purpose of the surge of TNF-
synthesis in injured muscle fibers is to activate p38 and thus to turn on myogenic differentiation. Considering the importance of p38 activation in myogenic differentiation, the role of TNF-
in muscle regeneration appears to be more significant than previously thought.
The myogenic program is a highly complex signaling network, and p38 is involved in several key steps of the program. We show in the present study that multiple p38-mediated steps of the myogenic program are TNF- signaling dependent, including MEF-2 phosphorylation, induction of myogenin and p21 expression, and suppression of cyclin D1 expression. MEF-2 phosphorylation is required for the expression of the majority of muscle-specific genes that are synergistically activated by MEF-2 and MyoD (31). Myogenin plays a key role in executing the myogenic differentiation program (33). On the other hand, p21 and cyclin D1 are cell cycle regulators for cell cycle exit that are critical so that differentiation can take place (41). Although we measured these signaling events in intact muscle, they actually take place in activated satellite cells, not in myofibers and infiltrating inflammatory cells, which are terminally differentiated cells. These data consistently demonstrate an impairment of myogenic differentiation in the absence of TNF-
signaling during muscle regeneration.
The morphological abnormalities observed in regenerating p55/p75/ soleus muscle, including more severe and persistent inflammation, dystrophic calcification, and the formation of smaller myotubes, confirm that muscle regeneration is impaired in the absence of TNF- signaling. The morphological abnormalities can result from impairment of various aspects of muscle regeneration, including impairment of myogenesis due to the lack of p38 activation.
The results of force-frequency studies provide functional evidence that supports the histological data. In Fig. 8, the force-frequency curve for undamaged soleus (day 0) was shifted slightly to the right in p55/p75/ relative to WT. This response suggests that constitutive TNF- signaling influences the contractile properties of soleus muscle. Most likely, TNF modulates the expression of one or more regulatory proteins that affect the force-frequency characteristic. A partial listing of candidate proteins includes the voltage-sensitive dihydropyridine receptor, ryanodine-sensitive sarcoplasmic reticulum (SR) Ca2+ release channel, SR Ca2+-ATPase, myosin heavy chains, myosin light chains, troponin C, and tropomyosin. This issue, while intriguing, was not the focus of our present study. No attempt has been made to identify the proteins responsible for differences between groups at day 0.
Inflammation is a key response to muscle injury (44) by virtue of its role in phagocytosis and satellite cell proliferation and differentiation (35). Because an important function of TNF- signaling is to amplify inflammatory response, the presence of more severe inflammation in injured p55/p75/ soleus appears counterintuitive. Yet, despite the presence of more severe inflammation, regeneration in p55/p75/ soleus was still impaired. These observations suggest that there is a compensatory increase of inflammation to promote regeneration as a result of the deficiency in muscle regeneration in p55/p75/ muscle; nevertheless, with the lack of TNF-
signaling, increased inflammation is still ineffective in promoting regeneration. Thus TNF-
signaling appears to be a key component of inflammation that promotes muscle regeneration. TNF-
is known to stimulate phagocytosis (30) and a chemotactic response (45), which facilitate muscle regeneration. The present study shows that in addition to the previously known effects, TNF-
signaling is required for p38-mediated myogenesis.
That skeletal muscle develops in TNF- receptor-knockout mice almost normally, although with different mechanical properties (7), does not automatically preclude TNF-
from being a physiological regulator of myogenesis, because a compensatory mechanism may replace the role played by TNF-
. Previous studies showed that in TNF-
-null mice, any role played by TNF-
could be performed effectively by the upregulation of other cytokines. In the absence of TNF-
, a number of cytokines, including IL-12, INF-
, and IL-1, are upregulated (12, 17, 42). The networking of these cytokines is capable of activating macrophages and modulating myoblast proliferation and fusion (12, 18). An analogy can be found in MyoD-knockout mice. MyoD-knockout mice still develop muscle because of a redundancy in the role of Myf-5 (40). A possible explanation for the difference observed between newborn animals and adult animals that undergo muscle regeneration is that in newborn animals, the compensatory mechanism plays out over time, whereas injury-induced regeneration is an acute response, especially with regard to regeneration induced by snake venom, in which degeneration and inflammation develop more quickly than other types of injury (25), so that a role of TNF-
signaling can more readily be appreciated.
In summary, the present study provides new evidence that TNF- has an important physiological role in regulating skeletal muscle regeneration. These data are helpful in sorting out the details of the mechanism that initiates muscle regeneration, particularly myogenesis, in response to injury. The results described herein also have clinical implications. TNF-
has long been considered a therapeutic target for inflammatory diseases. Anti-TNF-
strategies have gained popularity clinically in treating a variety of inflammatory conditions. Our data suggest that long-term use of anti-TNF-
reagents may impair skeletal muscle adaptation. Thus caution should be exercised in using anti-TNF-
strategies.
![]() |
GRANTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Cabane C, Englaro W, Yeow K, Ragno M, and Dérijard B. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38 pathway. Am J Physiol Cell Physiol 284: C658C666, 2003.
3. Cantini M and Carraro U. Macrophage-released factor stimulates selectively myogenic cells in primary muscle culture. J Neuropathol Exp Neurol 54: 121128, 1995.[ISI][Medline]
4. Cantini M, Massimino ML, Rapizzi E, Rossini K, Catani C, Dalla Libera L, and Carraro U. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. Biochem Biophys Res Commun 216: 4953, 1995.[CrossRef][ISI][Medline]
5. Chazaud B, Sonnet C, Lafuste P, Bassez G, Rimaniol AC, Poron F, Authier FJ, Dreyfus PA, and Gherardi RK. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J Cell Biol 163: 11331143, 2003.
6. Close RI. Dynamic properties of mammalian skeletal muscles. Physiol Rev 52: 129197, 1972.
7. Collins RA and Grounds MD. The role of tumor necrosis factor- (TNF-
) in skeletal muscle regeneration: studies in TNF-
/ and TNF-
//LT-
/ mice. J Histochem Cytochem 49: 9891001, 2001.
8. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, and Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 66536662, 1997.
9. Cuenda A and Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 274: 43414346, 1999.
10. De Bleecker JL, Meire VI, Declercq W, and Van Aken EH. Immunolocalization of tumor necrosis factor- and its receptors in inflammatory myopathies. Neuromuscul Disord 9: 239246, 1999.[CrossRef][ISI][Medline]
11. Decoster E, Cornelis S, Vanhaesebroeck B, and Fiers W. Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) differentially modulate cellular sensitivity to TNF/LT-
cytotoxicity in L929 cells. J Cell Biol 143: 20572065, 1998.
12. De Maeyer E and De Maeyer-Guignard J. Interferons. In: The Cytokine Handbook (3rd ed.), edited by Thomson AW. San Diego, CA: Academic, 1998, p. 491516.
13. Durham WJ, Li YP, Gerken E, Farid M, Arbogast S, Wolfe RR, and Reid MB. Fatiguing exercise reduces DNA binding activity of NF-B in skeletal muscle nuclei. J Appl Physiol 97: 17401745, 2004.
14. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, and Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265: 1449714504, 1990.
15. Han J and Molkentin JD. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc Med 10: 1922, 2000.[CrossRef][ISI][Medline]
16. Hawke TJ and Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 91: 534551, 2001.
17. Hodge-Dufour J, Marino MW, Horton MR, Jungbluth A, Burdick MD, Strieter RM, Noble PW, Hunter CA, and Puré E. Inhibition of interferon induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci USA 95: 1380613811, 1998.
18. Ji SQ, Neustrom S, Willis GM, and Spurlock ME. Proinflammatory cytokines regulate myogenic cell proliferation and fusion but have no impact on myotube protein metabolism or stress protein expression. J Interferon Cytokine Res 18: 879888, 1998.[ISI][Medline]
19. Kaliman P, Canicio J, Testar X, Palacín M, and Zorzano A. Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-B and inducible nitric-oxide synthase define a common myogenic signaling pathway. J Biol Chem 274: 1743717444, 1999.
20. Khurana A and Dey CS. Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation. J Muscle Res Cell Motil 25: 645655, 2004.[CrossRef][ISI][Medline]
21. Kuru S, Inukai A, Kato T, Liang Y, Kimura S, and Sobue G. Expression of tumor necrosis factor- in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 105: 217224, 2003.[ISI][Medline]
22. Lavoie JN, L'Allemain G, Brunet A, Müller R, and Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 2060820616, 1996.
23. Lee J, Hong F, Kwon S, Kim SS, Kim DO, Kang HS, Lee SJ, Ha J, and Kim SS. Activation of p38 MAPK induces cell cycle arrest via inhibition of Raf/ERK pathway during muscle differentiation. Biochem Biophys Res Commun 298: 765771, 2002.[CrossRef][ISI][Medline]
24. Lee KH, Kim DG, Shin NY, Song WK, Kwon H, Chung CH, and Kang MS. NF-B-dependent expression of nitric oxide synthase is required for membrane fusion of chick embryonic myoblasts. Biochem J 324: 237242, 1997.[ISI][Medline]
25. Lefaucheur JP and Sébille A. The cellular events of injured muscle regeneration depend on the nature of the injury. Neuromuscul Disord 5: 501509, 1995.[CrossRef][ISI][Medline]
26. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, and Reid MB. TNF- acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19: 362370, 2005.
27. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, and Reid MB. TNF- increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17: 10481057, 2003.
28. Li YP and Schwartz RJ. TNF- regulates early differentiation of C2C12 myoblasts in an autocrine fashion. FASEB J 15: 14131415, 2001.
29. Lundberg IE and Dastmalchi M. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 28: 799822, 2002.[CrossRef][ISI][Medline]
30. Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 25, Suppl 2: S20S22, 1995.[ISI][Medline]
31. McKinsey TA, Zhang CL, and Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27: 4047, 2002.[CrossRef][ISI][Medline]
32. Meriane M, Roux P, Primig M, Fort P, and Gauthier-Rouvière C. Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways. Mol Biol Cell 11: 25132528, 2000.
33. Molkentin JD and Olson EN. Defining the regulatory networks for muscle development. Curr Opin Genet Dev 6: 445453, 1996.[CrossRef][ISI][Medline]
34. Page K, Li J, and Hershenson MB. p38 MAP kinase negatively regulates cyclin D1 expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 280: L955L964, 2001.
35. Penn BH, Bergstrom DA, Dilworth FJ, Bengal E, and Tapscott SJ. A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev 18: 23482353, 2004.
36. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M, and Wang JYJ. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14: 574584, 2000.
37. Reid MB and Li YP. Cytokines and oxidative signaling in skeletal muscle cells. Acta Physiol Scand 171: 225232, 2001.[CrossRef][ISI][Medline]
38. Robertson TA, Maley MA, Grounds MD, and Papadimitriou JM. The role of macrophages in skeletal muscle regeneration with particular reference to chemotaxis. Exp Cell Res 207: 321331, 1993.[CrossRef][ISI][Medline]
39. Rousse S, Lallemand F, Montarras D, Pinset C, Mazars A, Prunier C, Atfi A, and Dubois C. Transforming growth factor- inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway. J Biol Chem 276: 4696146967, 2001.
40. Rudnicki MA, Braun T, Hinuma S, and Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 71: 383390, 1992.[CrossRef][ISI][Medline]
41. Schafer KA. The cell cycle: a review. Vet Pathol 35: 461478, 1998.[Abstract]
42. Storkus WJ, Tahara H, and Lotze MT. Interleukin-12. In: The Cytokine Handbook (3rd ed.), edited by Thomson AW. San Diego, CA: Academic, 1998, p. 391426.
43. Tews DS and Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55: 342347, 1996.[ISI][Medline]
44. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc 27: 10221032, 1995.[ISI][Medline]
45. Torrente Y, El Fahime E, Caron NJ, Del Bo R, Belicchi M, Pisati F, Tremblay JP, and Bresolin N. Tumor necrosis factor- (TNF-
) stimulates chemotactic response in mouse myogenic cells. Cell Transplant 12: 91100, 2003.[ISI][Medline]
46. Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, and Simeonova PP. Physiological role of tumor necrosis factor in traumatic muscle injury. FASEB J 16: 16301632, 2002.
47. Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY, and Puri PL. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 20: 39513964, 2000.
48. Xu Q, Yu L, Liu L, Cheung CF, Li X, Yee SP, Yang XJ, and Wu Z. p38 Mitogen-activated protein kinase-, calcium-calmodulin-dependent protein kinase-, and calcineurin-mediated signaling pathways transcriptionally regulate myogenin expression. Mol Biol Cell 13: 19401952, 2002.
49. Yeow K, Cabane C, Turchi L, Ponzio G, and Dérijard B. Increased MAPK signaling during in vitro muscle wounding. Biochem Biophys Res Commun 293: 112119, 2002.[CrossRef][ISI][Medline]
50. Zádor E, Mendler L, Takács V, de Bleecker J, and Wuytack F. Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF- and its receptors, TNFR-60 and TNFR-80. Muscle Nerve 24: 10581067, 2001.[CrossRef][ISI][Medline]
51. Zetser A, Gredinger E, and Bengal E. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation: participation of the MEF2C transcription factor. J Biol Chem 274: 51935200, 1999.
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |